Overview of the drug development pipeline for regenerative medicines for Parkinson’s Disease
Parkinson’s disease is a long-term neurodegenerative disorder that affects the motor functions. This disease develops over time and primarily affects the older population aged above 60 years. The degree of impairment varies with each patient. Recently, it has been reported that a large volume of younger population has been impacted by Parkinson’s disease. Several pharmaceutical companies are focusing on increasing dopamine levels in the brain, to reverse or mitigate the effect of Parkinson’s disease. Individuals may be suffering from Idiopathic Parkinsonism or Atypical parkinsonism, with varying causes of diseases. According to the stem cell therapy for osteoarthritis market analysis, Technavio’s market research analysts have predicted that regenerative medicine industry growth will be witnessed with the increasing number of incidence of the Parkinson’s disease will boost the extensive research on various gene therapy and cell therapy will be conducted to develop regenerative therapeutics for Parkinson’s Disease in the forthcoming years.
Our market research analysts have also identified that most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost the same amount of drug molecules are under the phase I/II and phase I drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase II stage.
Regenerative medicine market worth: Companies covered
According to Regenerative Medicine Market forecast, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of regenerative medicines for Parkinson’s Disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- BRAINSTORM CELL THERAPEUTICS
- CYTO THERAPEUTICS
- PREVAIL THERAPEUTICS
Therapeutic assessment of the drug development pipeline for regenerative medicines for Parkinson’s Disease by route of administration
- Intravenous
- Intracerebral
- Implant
- Intrastriatal
- Intraputaminal
The intravenous route of administration (ROA) comprises of the administration of drug substances through the veins in the body. It has analyzed that four therapeutic molecules are being developed for administration through intravenous mode.
Therapeutic assessment of the drug development pipeline for regenerative medicines for Parkinson’s Disease by therapeutic modality
- Gene therapy
- Cell therapy
According to this pipeline analysis report, gene therapies are the primary therapies employed in the drug development pipeline for regenerative medicine for Parkinson’s disease. Numerous gene therapies are being developed to inhibit the growth of the mutant genes and fix the mutated gene. This factor will propel the regenerative medicine market value
Technavio also offers customization on reports based on specific client requirement.